NYSE:IQV

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.


Snowflake Analysis

Reasonable growth potential with questionable track record.


Similar Companies

Share Price & News

How has IQVIA Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IQV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.1%

IQV

1.0%

US Life Sciences

2.9%

US Market


1 Year Return

9.0%

IQV

19.6%

US Life Sciences

8.9%

US Market

Return vs Industry: IQV underperformed the US Life Sciences industry which returned 19.6% over the past year.

Return vs Market: IQV matched the US Market which returned 8.9% over the past year.


Shareholder returns

IQVIndustryMarket
7 Day1.1%1.0%2.9%
30 Day12.8%9.3%10.6%
90 Day11.1%16.0%5.1%
1 Year9.0%9.0%19.9%19.6%11.4%8.9%
3 Year75.5%75.5%83.9%82.5%34.3%25.4%
5 Year115.9%115.9%130.4%127.5%60.7%42.7%

Price Volatility Vs. Market

How volatile is IQVIA Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is IQVIA Holdings undervalued compared to its fair value and its price relative to the market?

136.26x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: IQV ($151.21) is trading above our estimate of fair value ($98.3)

Significantly Below Fair Value: IQV is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: IQV is poor value based on its PE Ratio (136.3x) compared to the Life Sciences industry average (37.6x).

PE vs Market: IQV is poor value based on its PE Ratio (136.3x) compared to the US market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: IQV is poor value based on its PEG Ratio (3.3x)


Price to Book Ratio

PB vs Industry: IQV is good value based on its PB Ratio (5.2x) compared to the US Life Sciences industry average (5.9x).


Next Steps

Future Growth

How is IQVIA Holdings forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

41.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IQV's forecast earnings growth (41.7% per year) is above the savings rate (2.2%).

Earnings vs Market: IQV's earnings (41.7% per year) are forecast to grow faster than the US market (22.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: IQV's revenue (7.7% per year) is forecast to grow slower than the US market (8.8% per year).

High Growth Revenue: IQV's revenue (7.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IQV's Return on Equity is forecast to be high in 3 years time (21.7%)


Next Steps

Past Performance

How has IQVIA Holdings performed over the past 5 years?

4.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IQV has high quality earnings.

Growing Profit Margin: IQV's current net profit margins (1.9%) are lower than last year (2.4%).


Past Earnings Growth Analysis

Earnings Trend: IQV's earnings have grown by 4.3% per year over the past 5 years.

Accelerating Growth: IQV's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: IQV had negative earnings growth (-13.3%) over the past year, making it difficult to compare to the Life Sciences industry average (10.6%).


Return on Equity

High ROE: IQV's Return on Equity (4.3%) is considered low.


Next Steps

Financial Health

How is IQVIA Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: IQV's short term assets ($4.3B) exceed its short term liabilities ($3.9B).

Long Term Liabilities: IQV's short term assets ($4.3B) do not cover its long term liabilities ($13.4B).


Debt to Equity History and Analysis

Debt Level: IQV's debt to equity ratio (208.3%) is considered high.

Reducing Debt: IQV had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: IQV's debt is not well covered by operating cash flow (12.1%).

Interest Coverage: IQV's interest payments on its debt are not well covered by EBIT (2x coverage).


Balance Sheet


Next Steps

Dividend

What is IQVIA Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IQV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IQV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IQV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IQV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: IQV is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IQV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

Ari Bousbib (58yo)

3.67yrs

Tenure

US$22,139,776

Compensation

Mr. Ari Bousbib serves as Chairman and Chief Executive Officer at IQVIA Holdings Inc. since October 2016 and also serves as its President. He has been the Chairman, Chief Executive Officer and President of ...


CEO Compensation Analysis

Compensation vs Market: Ari's total compensation ($USD22.14M) is above average for companies of similar size in the US market ($USD11.52M).

Compensation vs Earnings: Ari's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Ari Bousbib
Chairman3.67yrsUS$22.14m0.63% $180.7m
Michael McDonnell
Executive VP & CFO4.5yrsUS$2.95m0.0084% $2.4m
Eric Sherbet
Executive VP2.25yrsUS$2.37mno data
W. Staub
President of Research & Development Solutions3.58yrsUS$2.64m0.0065% $1.9m
Kevin Knightly
President of Technology & Commercial Solutions3.67yrsUS$2.61mno data
Emmanuel Korakis
Senior VP1.58yrsno datano data
Jeffrey Spaeder
Senior VPno datano datano data
Alejandro Martinez
Chief Information Officer5.5yrsno datano data
Andrew Markwick
Senior VP of Investor Relations & Treasuryno datano datano data
Marla Kessler
Senior Vice President of Strategyno datano datano data

3.7yrs

Average Tenure

55yo

Average Age

Experienced Management: IQV's management team is considered experienced (3.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ari Bousbib
Chairman3.67yrsUS$22.14m0.63% $180.7m
John Danhakl
Independent Director3.67yrsUS$282.39k0.039% $11.2m
John Connaughton
Independent Director12.42yrsno datano data
John Leonard
Lead Director1.92yrsUS$357.39k0.0051% $1.5m
Jonathan Coslet
Independent Director17.42yrsno datano data
Ronald Rittenmeyer
Independent Director3.67yrsUS$334.89k0.033% $9.4m
Colleen Goggins
Independent Director2.92yrsUS$314.89k0.0038% $1.1m
Todd Sisitsky
Independent Director3.67yrsno datano data
James Fasano
Independent Director3.67yrsno datano data
Carol Burt
Independent Director1.33yrsUS$274.89k0.0016% $450.5k

3.7yrs

Average Tenure

59.5yo

Average Age

Experienced Board: IQV's board of directors are considered experienced (3.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

IQVIA Holdings Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: IQVIA Holdings Inc.
  • Ticker: IQV
  • Exchange: NYSE
  • Founded: 1982
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$28.876b
  • Shares outstanding: 190.96m
  • Website: https://www.iqvia.com

Number of Employees


Location

  • IQVIA Holdings Inc.
  • 4820 Emperor Boulevard
  • Durham
  • North Carolina
  • 27703
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IQVNYSE (New York Stock Exchange)YesCommon StockUSUSDMay 2013
QTSDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2013
0JDMLSE (London Stock Exchange)YesCommon StockGBUSDMay 2013
IQV *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMay 2013
IQVHWBAG (Wiener Boerse AG)YesCommon StockATEURMay 2013
I1QV34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 4 REPR 1 COMBRBRLJan 2020

Biography

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 05:41
End of Day Share Price2020/06/04 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.